Research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Get Free Report) in a note issued to investors on Saturday. The brokerage set a "hold" rating on the stock.
Brooklyn ImmunoTherapeutics Trading Up 0.6%
Shares of Brooklyn ImmunoTherapeutics stock traded up $0.04 during trading on Friday, reaching $6.68. The company's stock had a trading volume of 126,157 shares, compared to its average volume of 750,885. The stock has a 50-day moving average price of $6.30 and a two-hundred day moving average price of $3.24. The stock has a market capitalization of $392.96 million, a P/E ratio of -2.94 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $5.10 and a one year high of $8.31.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Read More
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
